EA202090516A2 - Бициклические гетероциклы в качестве ингибиторов fgfr - Google Patents

Бициклические гетероциклы в качестве ингибиторов fgfr

Info

Publication number
EA202090516A2
EA202090516A2 EA202090516A EA202090516A EA202090516A2 EA 202090516 A2 EA202090516 A2 EA 202090516A2 EA 202090516 A EA202090516 A EA 202090516A EA 202090516 A EA202090516 A EA 202090516A EA 202090516 A2 EA202090516 A2 EA 202090516A2
Authority
EA
Eurasian Patent Office
Prior art keywords
bicyclic heterocycles
fgfr inhibitors
fgfr
inhibitors
fgfrs
Prior art date
Application number
EA202090516A
Other languages
English (en)
Other versions
EA202090516A3 (ru
Inventor
Япин Сунь
Лян Лу
Вэньцин Яо
Цзиньцун Чжо
Лянсин Ву
Мэйчжун Сюй
Дин-Цюань Цянь
Фэнлэй Чжан
Чуньхун Хэ
Original Assignee
Инсайт Холдингс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсайт Холдингс Корпорейшн filed Critical Инсайт Холдингс Корпорейшн
Publication of EA202090516A2 publication Critical patent/EA202090516A2/ru
Publication of EA202090516A3 publication Critical patent/EA202090516A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к бициклическим гетероциклам и фармацевтическим композициям на их основе, которые представляют собой ингибиторы одного или более ферментов-рецепторов фактора роста фибробластов (FGFR) и являются подходящими для лечения заболеваний, связанных с FGFR, таких как рак.
EA202090516A 2013-04-19 2014-04-18 Бициклические гетероциклы в качестве ингибиторов fgfr EA202090516A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361813782P 2013-04-19 2013-04-19

Publications (2)

Publication Number Publication Date
EA202090516A2 true EA202090516A2 (ru) 2020-06-30
EA202090516A3 EA202090516A3 (ru) 2020-10-30

Family

ID=50983108

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201592005A EA035095B1 (ru) 2013-04-19 2014-04-18 Бициклические гетероциклы в качестве ингибиторов fgfr
EA202090516A EA202090516A3 (ru) 2013-04-19 2014-04-18 Бициклические гетероциклы в качестве ингибиторов fgfr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201592005A EA035095B1 (ru) 2013-04-19 2014-04-18 Бициклические гетероциклы в качестве ингибиторов fgfr

Country Status (35)

Country Link
US (5) US9533984B2 (ru)
EP (2) EP2986610B9 (ru)
JP (3) JP6449244B2 (ru)
KR (2) KR102269032B1 (ru)
CN (3) CN109912594A (ru)
AR (1) AR096097A1 (ru)
AU (3) AU2014253798C1 (ru)
BR (1) BR112015026307B1 (ru)
CA (2) CA2909207C (ru)
CL (1) CL2015003089A1 (ru)
CR (1) CR20150578A (ru)
CY (1) CY1120556T1 (ru)
DK (1) DK2986610T5 (ru)
EA (2) EA035095B1 (ru)
EC (1) ECSP15048555A (ru)
ES (2) ES2893725T3 (ru)
HK (2) HK1221462A1 (ru)
HR (1) HRP20180365T2 (ru)
HU (1) HUE036571T2 (ru)
IL (2) IL241982B (ru)
LT (1) LT2986610T (ru)
ME (1) ME03015B (ru)
MX (2) MX367878B (ru)
MY (1) MY181497A (ru)
NO (1) NO3087075T3 (ru)
PE (1) PE20152033A1 (ru)
PH (2) PH12015502383A1 (ru)
PL (1) PL2986610T4 (ru)
PT (1) PT2986610T (ru)
RS (1) RS56924B9 (ru)
SG (2) SG11201508328PA (ru)
SI (1) SI2986610T1 (ru)
TW (2) TWI715901B (ru)
UA (1) UA120087C2 (ru)
WO (1) WO2014172644A2 (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EA036592B1 (ru) 2012-06-13 2020-11-26 Инсайт Холдингс Корпорейшн Замещенные трициклические соединения как ингибиторы fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN109912594A (zh) 2013-04-19 2019-06-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
TR201907147T4 (tr) 2013-07-18 2019-06-21 Taiho Pharmaceutical Co Ltd Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
MX367723B (es) 2013-10-25 2019-09-03 Novartis Ag Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4.
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
MA51229A (fr) 2015-02-20 2021-03-24 Incyte Corp Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
MA41551A (fr) * 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10434103B2 (en) 2015-03-31 2019-10-08 Taiho Pharmaceutical Co., Ltd. Crystal of 3,5-disubstituted benzene alkynyl compound
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
WO2017202390A1 (zh) * 2016-05-27 2017-11-30 杭州英创医药科技有限公司 作为fgfr4抑制剂的杂环化合物
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
US11192890B2 (en) * 2017-03-03 2021-12-07 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
AR111960A1 (es) * 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
SI3651768T1 (sl) 2017-07-13 2024-05-31 Chempartner Corporation Heterociklični inhibitorji atr kinaze
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
ES2980333T3 (es) 2018-03-19 2024-09-30 Taiho Pharmaceutical Co Ltd Composición farmacéutica que incluye alquil-sulfato de sodio
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GB201915828D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115715201A (zh) * 2020-03-02 2023-02-24 约翰霍普金斯大学 葡萄糖雷公藤甲素缀合物及其用途
CN111960932B (zh) * 2020-09-16 2022-11-08 沈阳药科大学 二氯雷琐酚类化合物及其制备方法和医药用途
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CN113527311B (zh) * 2021-08-23 2022-05-06 中南大学湘雅医院 Fgfr4抑制剂、组合物及其在药物制备中的用途
WO2023039828A1 (en) * 2021-09-17 2023-03-23 Nutshell Biotech (Shanghai) Co., Ltd. Fused ring compounds as inhibitors of fgfr4 tyrosine kinases
WO2023091746A1 (en) 2021-11-22 2023-05-25 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (811)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE280853C (ru)
US850370A (en) 1906-06-05 1907-04-16 William L Hynes Water-automobile.
DE2156720A1 (de) 1971-11-16 1973-05-24 Bayer Ag Pyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine
US3894021A (en) 1974-01-28 1975-07-08 Squibb & Sons Inc Derivatives of 1,7-dihydro-2H-pyrazolo{8 4{40 ,3{40 :5,6{9 pyrido{8 4,3-D{9 pyrimidine-2,4-(3H)-diones
JPS5120580B2 (ru) 1974-06-19 1976-06-25
JPS5120580A (en) 1974-08-08 1976-02-18 Nitto Electric Ind Co 4 futsukaechirenjugotaihifukudensenno seizohoho
US4347348A (en) 1978-06-05 1982-08-31 Chernikhov Alexei Y Heat-resistant heterocyclic polymers and methods for producing same
FR2428654A1 (fr) 1978-06-13 1980-01-11 Chernikhov Alexei Polymeres heterocycliques thermostables et leurs procedes de preparation
CH635828A5 (de) 1978-08-30 1983-04-29 Ciba Geigy Ag N-substituierte imide und bisimide.
CH641470A5 (de) 1978-08-30 1984-02-29 Ciba Geigy Ag Imidgruppen enthaltende silane.
US4339267A (en) 1980-01-18 1982-07-13 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
US4405519A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Di-Acetylene-terminated polyimide derivatives
US4405786A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives and an dienophile having ethylene groups
US4405520A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polymide derivatives and dienophiles having terminal maleimide grops
US4402878A (en) 1980-10-22 1983-09-06 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives with a polyimide having terminal non-conjugated acetylene groups
JPS5857170A (ja) 1981-09-30 1983-04-05 シャープ株式会社 学習機
JPS5873576U (ja) 1981-11-12 1983-05-18 沖電気工業株式会社 コネクタのロツク構造
US4460773A (en) 1982-02-05 1984-07-17 Lion Corporation 1-Phenyl-1H-pyrazolo [3,4-b]pyrazine derivatives and process for preparing same
JPS5926040U (ja) 1982-08-12 1984-02-17 井出　正一 ロ−プ掛締付け器
DE3432983A1 (de) 1983-09-07 1985-04-18 Lion Corp., Tokio/Tokyo 1,5-disubstituierte 1h-pyrazolo(3,4-b)-pyrazin-derivate und antitumormittel, die diese enthalten
JPH029895Y2 (ru) 1984-11-08 1990-03-12
JPH0348656Y2 (ru) 1985-05-10 1991-10-17
JPS62273979A (ja) 1986-05-21 1987-11-28 Lion Corp １，５−置換−１Ｈ−ピラゾロ〔３，４−ｂ〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
JPS6310630A (ja) 1986-06-23 1988-01-18 Teijin Ltd 芳香族ポリアミドイミドエ−テルの製造法
JPS6317882A (ja) 1986-07-09 1988-01-25 Lion Corp ５−置換−１Ｈ−ピラゾロ〔３，４−ｂ〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
US4859672A (en) 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US4874803A (en) 1987-09-21 1989-10-17 Pennwalt Corporation Dianhydride coupled polymer stabilizers
DE3814549A1 (de) 1987-10-30 1989-05-18 Bayer Ag N-substituierte derivate von 1-desoxynojirimycin und 1-desoxymannonojirimycin, verfahren zu deren herstellung und deren verwendung in arzneimitteln
JPH029895A (ja) 1988-06-28 1990-01-12 Lion Corp ヌクレオシド類似化合物及び抗腫瘍剤
DD280853A1 (de) 1989-03-21 1990-07-18 Akad Nauk Sssr Bindemittel fuer elektroden, vorzugsweise fuer polymerelektroden
US5159054A (en) 1989-05-16 1992-10-27 The United States Of America As Represented By The Secretary Of The Navy Synthesis of phthalonitrile resins containing ether and imide linkages
JP2845957B2 (ja) 1989-07-17 1999-01-13 三井化学株式会社 イミド環を有する新規ジフェノール類およびその製造方法
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
DE3937633A1 (de) 1989-11-11 1991-05-16 Bayer Ag Heterocyclische verbindungen und deren verwendung als pigmente und farbstoffe
CA2072597C (en) 1989-12-28 1998-09-22 Hans-Tobias Macholdt Biscationic acid amide and imide derivatives and processes for their preparation
EP0506867B1 (de) 1989-12-28 1995-09-20 Hoechst Aktiengesellschaft Biskationische säureamid- und -imidderivate als ladungssteuermittel
JP2883670B2 (ja) 1990-03-23 1999-04-19 三井化学株式会社 イミド環を有する新規ビスフェノール類およびその製造方法
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
NZ240089A (en) 1990-10-03 1993-04-28 Commw Scient Ind Res Org Diaminobisimide compounds and compositions comprising such compounds for curing epoxy resins
JPH04158084A (ja) 1990-10-22 1992-06-01 Fuji Photo Film Co Ltd 記録材料
JPH04179576A (ja) 1990-11-14 1992-06-26 Fuji Photo Film Co Ltd 記録材料
JPH04328121A (ja) 1991-04-26 1992-11-17 Sumitomo Bakelite Co Ltd 半導体封止用エポキシ樹脂組成物
JP3147902B2 (ja) 1991-06-14 2001-03-19 ファルマシア・アンド・アップジョン・カンパニー イミダゾ〔１，５−ａ〕キノキサリン
DE4119767A1 (de) 1991-06-15 1992-12-17 Dresden Arzneimittel Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3279635B2 (ja) 1992-05-18 2002-04-30 鐘淵化学工業株式会社 ヒドロシリル基含有イミド化合物
JP3232123B2 (ja) 1992-05-20 2001-11-26 鐘淵化学工業株式会社 硬化性組成物
EP0642510A4 (en) 1992-05-28 1997-04-02 Commw Scient Ind Res Org BISMALEIMIDE COMPOUNDS.
JPH08504196A (ja) 1992-12-07 1996-05-07 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション ビスナドイミド
JPH08506189A (ja) 1993-01-11 1996-07-02 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 非線形光学的性質を有する多環式芳香族化合物
AU4293193A (en) 1993-04-28 1994-11-21 Du Pont Merck Pharmaceutical Company, The Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
US5536725A (en) 1993-08-25 1996-07-16 Fmc Corporation Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
CA2277954A1 (en) 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
BR9408531A (pt) 1994-02-02 1997-08-05 Lilly Co Eli Inibidores da protease hiv e intermediários
US5480887A (en) 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
ATE190978T1 (de) 1994-11-14 2000-04-15 Warner Lambert Co 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
JPH09188812A (ja) 1996-01-11 1997-07-22 Mitsui Toatsu Chem Inc 結晶化促進剤
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
CA2262692C (en) 1996-08-06 2002-06-11 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
EP0927167A1 (en) 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
JP3669783B2 (ja) 1996-08-21 2005-07-13 三井化学株式会社 有機電界発光素子
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
AU6908398A (en) 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
CA2271157A1 (en) 1997-02-05 1998-08-06 Warner-Lambert Company Pyrido[2,3-d]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
WO1998046609A1 (en) 1997-04-11 1998-10-22 Abbott Laboratories Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
EP1001945B1 (en) 1997-05-28 2011-03-02 Aventis Pharmaceuticals Inc. QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
CA2300478A1 (en) 1997-08-11 1999-02-18 Cor Therapeutics, Inc. Selective factor xa inhibitors
ES2235353T3 (es) 1997-08-20 2005-07-01 Warner-Lambert Company Llc Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
JPH11171865A (ja) 1997-12-04 1999-06-29 Yoshitomi Pharmaceut Ind Ltd 縮合ヘテロ環化合物
CN1290249A (zh) 1998-02-20 2001-04-04 武田药品工业株式会社 氨基胍腙衍生物、制法及制剂
JP2002515490A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド Ｐａｒｐ活性を抑制する縮合三環化合物
US20040044012A1 (en) * 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
CN1138778C (zh) * 1998-05-26 2004-02-18 沃尼尔·朗伯公司 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
WO1999064400A1 (en) 1998-06-12 1999-12-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
JP2000123973A (ja) 1998-10-09 2000-04-28 Canon Inc 有機発光素子
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CZ20011394A3 (cs) 1998-10-23 2001-12-12 F. Hoffmann-La Roche Ag Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19912638A1 (de) 1999-03-20 2000-09-21 Bayer Ag Naphthylcarbonsäureamid-substituierte Sulfonamide
DE19920790A1 (de) 1999-05-06 2000-11-09 Bayer Ag Bis-Sulfonamide mit anti-HCMV-Wirkung
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP4041624B2 (ja) 1999-07-21 2008-01-30 三井化学株式会社 有機電界発光素子
CA2384188C (en) 1999-09-24 2008-06-17 Janssen Pharmaceutica N.V. Antiviral compositions
DE19946289A1 (de) 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
RU2265606C2 (ru) 1999-10-21 2005-12-10 Ф.Хоффманн-Ля Рош Аг ГЕТЕРОАЛКИЛАМИНОЗАМЕЩЕННЫЕ БИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ГЕТЕРОЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ р38
WO2001029041A1 (en) 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CN100432055C (zh) 1999-12-29 2008-11-12 惠氏公司 三环蛋白激酶抑制剂
BR0017010A (pt) 2000-01-24 2002-11-05 Warner Lambert Co Agentes antibacterianos 3-aminoquinazolin-2,4-diona
WO2001055148A1 (en) 2000-01-27 2001-08-02 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
US7041675B2 (en) 2000-02-01 2006-05-09 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as PARP inhibitors
AU3664401A (en) 2000-02-04 2001-08-14 Cor Therapeutics Inc Platelet adp receptor inhibitors
JP4837864B2 (ja) 2000-02-09 2011-12-14 ノバルティス アーゲー 血管形成および／またはｖｅｇｆ受容体チロシンキナーゼを阻害するピリジン誘導体
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
JP2001265031A (ja) 2000-03-15 2001-09-28 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び、電子写真装置
DE10012549A1 (de) 2000-03-15 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
NZ521978A (en) 2000-04-28 2004-10-29 Acadia Pharm Inc Compounds that affect cholinergic receptors and are particularly muscarinic agonists
WO2001085722A1 (en) 2000-05-05 2001-11-15 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
CN1439008A (zh) 2000-06-23 2003-08-27 布里斯托尔-迈尔斯斯奎布药品公司 作为因子xa抑制剂的1－(杂芳环基－苯基)－稠合吡唑衍生物
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
IL154310A0 (en) 2000-08-07 2003-09-17 Neurogen Corp Heterocyclic compounds as ligands of the gabaa receptor
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
EP1315490B1 (en) 2000-09-06 2008-11-12 Ortho-McNeil Pharmaceutical, Inc. A method for treating allergies using substituted pyrazoles
GB0025782D0 (en) 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
JP2002296731A (ja) 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd 熱現像カラー画像記録材料
AU2002255263B2 (en) 2001-04-16 2006-12-14 Eisai R&D Management Co., Ltd. Novel 1H-indazole compound
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
PL366934A1 (en) 2001-04-30 2005-02-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
WO2002094825A1 (fr) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2002102793A2 (en) 2001-06-19 2002-12-27 Warner-Lambert Company Llc Quinazolinediones as antibacterial agents
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
IL160139A0 (en) 2001-08-07 2004-06-20 Banyu Pharma Co Ltd Spiro compounds
EA007983B1 (ru) 2001-09-19 2007-02-27 Авентис Фарма С.А. Индолизины в качестве ингибиторов киназных белков
MXPA04004137A (es) 2001-10-30 2005-01-25 Novartis Ag Derivados de estauroesporina como inhibidores de la actividad de cinasa de tirosina del receptor flt3.
PL369259A1 (en) 2001-11-01 2005-04-18 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
CA2465711A1 (en) 2001-11-07 2003-05-15 F. Hoffmann-La Roche Ag Aminopyrimidines and pyridines
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
GB0129476D0 (en) 2001-12-10 2002-01-30 Syngenta Participations Ag Organic compounds
BR122016021801B8 (pt) 2002-01-22 2021-05-25 Warner Lambert Co compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
PT1482924E (pt) 2002-03-05 2008-08-27 Axys Pharm Inc Inibidores de proteases da cisteína catepsina
US6815519B2 (en) 2002-03-22 2004-11-09 Chung-Shan Institute Of Science & Technology Acidic fluorine-containing poly (siloxane amideimide) silica hybrids
EP1492790A1 (en) 2002-04-03 2005-01-05 F. Hoffmann-La Roche Ag Imidazo fused compounds
WO2003097609A1 (en) 2002-05-15 2003-11-27 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
JP4499342B2 (ja) 2002-05-16 2010-07-07 株式会社カネカ ＳｉＨ基を含有する含窒素有機系化合物の製造方法
US7034033B2 (en) 2002-05-23 2006-04-25 Chiron Corporation Substituted quinazolinone compounds
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
SG176311A1 (en) 2002-07-29 2011-12-29 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP4252534B2 (ja) 2002-08-06 2009-04-08 エフ．ホフマン−ラ ロシュ アーゲー ｐ−３８ＭＡＰキナーゼインヒビターとしての６−アルコキシ−ピリド−ピリミジン類
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
GB0223349D0 (en) 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
AU2003291310A1 (en) 2002-11-06 2004-06-03 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
EP1565475B1 (en) * 2002-11-18 2009-04-08 F. Hoffmann-La Roche Ag Diazinopyrimidines and their use as protein kinase inhibitors
AU2003288198A1 (en) 2002-11-28 2004-06-18 Schering Aktiengesellschaft CHK-,PDK- and AKT-inhibitory pyrimidines, their production and use as pharmaceutical agents
CA2508165C (en) 2002-12-06 2014-05-06 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
WO2004052862A1 (ja) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
JP2004203749A (ja) 2002-12-24 2004-07-22 Kanegafuchi Chem Ind Co Ltd ＳｉＨ基を含有する含窒素有機系化合物の製造方法
ATE433967T1 (de) 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
WO2004087053A2 (en) 2003-03-25 2004-10-14 Syrrx, Inc. Dipeptidyl peptidase inhibitors
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
KR20050111636A (ko) * 2003-04-10 2005-11-25 에프. 호프만-라 로슈 아게 피리미도 화합물
CA2523261C (en) 2003-05-05 2009-07-07 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives with crf activity
JP2004346145A (ja) 2003-05-21 2004-12-09 Teijin Ltd イミド組成物およびそれからなる樹脂組成物、及びその製造方法
CA2523015A1 (en) 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
PT1631295E (pt) 2003-06-06 2010-05-24 Arexis Ab Uso de compostos heterocíclicos condensados como inibidores de scce para o tratamento de doenças da pele
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2004113307A1 (ja) 2003-06-18 2004-12-29 Ube Industries, Ltd. ピリミジン−４−オン化合物の製造方法
JP2005015395A (ja) 2003-06-26 2005-01-20 Japan Science & Technology Agency 新規ピリミドピリミジンヌクレオシドとその構造類縁体
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
AU2004260689B8 (en) 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
US7390820B2 (en) 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
US20050070542A1 (en) 2003-09-03 2005-03-31 Hodgetts Kevin J. 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
WO2005028478A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
EP1670761B1 (en) 2003-10-01 2009-01-28 Xention Limited Tetrahydro-naphthalene and urea derivatives
JP4758349B2 (ja) 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
BRPI0416656A (pt) 2003-11-17 2007-01-16 Pfizer Prod Inc compostos de pirrolopirimidina úteis no tratamento do cáncer
WO2005056524A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
KR100703068B1 (ko) 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
MXPA06008257A (es) 2004-01-23 2006-08-31 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos.
ATE444068T1 (de) 2004-01-23 2009-10-15 Janssen Pharmaceutica Nv Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
JP2007529422A (ja) 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ， インコーポレイテッド 抗ウイルス治療
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1718645A1 (en) 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
AU2005219525B2 (en) 2004-02-27 2011-08-18 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
BRPI0508220A (pt) 2004-02-27 2007-07-17 Hoffmann La Roche derivados de pirazol heteroarila fundidos
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
WO2005085210A1 (ja) 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
WO2005092901A1 (ja) 2004-03-29 2005-10-06 Mitsui Chemicals, Inc. 新規化合物、および該化合物を用いた有機エレクトロニクス素子
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
JP2005320288A (ja) 2004-05-10 2005-11-17 Mitsui Chemicals Inc テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
BRPI0511512A (pt) 2004-05-27 2007-12-26 Pfizer Prod Inc derivados pirrolpirimidina úteis no tratamento do cáncer
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
JP2006028027A (ja) 2004-07-12 2006-02-02 Mitsui Chemicals Inc テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
RU2007111758A (ru) 2004-08-31 2008-10-10 Ф.Хоффманн-Ля Рош Аг (Ch) Аминопроизводные 7- амино-3-фенилдигидропиримидо [4,5-d] пиримидинонов, их получение и применение в качестве ингибиторов протеинкиназ
MX2007002096A (es) 2004-08-31 2007-03-29 Hoffmann La Roche Derivados de amida de 3-fenil-dihidropirimido[4,5-d] pirimidinonas, su fabricacion y su uso como agentes farmaceuticos.
NZ553087A (en) 2004-08-31 2010-12-24 Astrazeneca Ab Quinazolinone derivatives and their use as B-raf inhibitors
DE102004042667A1 (de) 2004-09-01 2006-03-30 Ewald Dörken Ag Mehrschichtige Gebäudewand
TWI370147B (en) 2004-09-10 2012-08-11 Ube Industries Modified polyimide resin and curable resin composition
CA2584412C (en) 2004-09-14 2017-05-09 Minerva Biotechnologies Corporation Methods for diagnosis and treatment of cancer
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
WO2006050162A2 (en) 2004-10-28 2006-05-11 Phenomix Corporation Imidazole derivatives
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR20070074610A (ko) 2004-11-08 2007-07-12 백스터 인터내셔널 인코포레이티드 튜불린 억제제의 나노미립자 조성물
CN101103016A (zh) 2004-11-18 2008-01-09 因塞特公司 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
US7795259B2 (en) 2004-11-22 2010-09-14 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
WO2006074293A2 (en) 2005-01-07 2006-07-13 President And Fellows Of Harvard College Bicyclic dihydropyrimidines as eg5 inhibitors
DE102005008310A1 (de) 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
CA2599662A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
JP2006284843A (ja) 2005-03-31 2006-10-19 Mitsui Chemicals Inc テトラカルボン酸誘導体を用いた電子写真感光体、電子写真装置
US20060223993A1 (en) 2005-04-01 2006-10-05 Connor Daniel M Colorant compounds, intermediates, and compositions
JP2006316054A (ja) 2005-04-15 2006-11-24 Tanabe Seiyaku Co Ltd 高コンダクタンス型カルシウム感受性ｋチャネル開口薬
KR100781704B1 (ko) 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
JP5016593B2 (ja) 2005-05-13 2012-09-05 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテイン・キナーゼ阻害剤としての化合物および組成物
US20060279115A1 (en) 2005-06-09 2006-12-14 Ash Tisdelle Vehicular head and neck safety system and method
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
ME02260B (me) 2005-07-01 2016-02-29 Medarex Inc Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
WO2007013964A1 (en) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
PT2099797E (pt) 2005-08-09 2011-01-04 Irm Llc Compostos e composições como inibidores de proteína-quinase
CN101291938A (zh) 2005-08-16 2008-10-22 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CA2620104A1 (en) 2005-08-25 2007-03-01 F. Hoffman-La Roche Ag Fused pyrazole as p38 map kinase inhibitors
US7678917B2 (en) 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
EA200800549A1 (ru) 2005-09-06 2008-08-29 Смитклайн Бичем Корпорейшн Региоселективный способ получения бензимидазолтиофенов
EP1925617B1 (en) 2005-09-15 2012-11-14 ASKA Pharmaceutical Co., Ltd. Heterocyclic compound, and production process and use thereof
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
WO2007038209A2 (en) 2005-09-23 2007-04-05 Schering Corporation Fused tetracyclic mglur1 antagonists as therapeutic agents
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
AU2006302179C1 (en) 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CA2624965A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
WO2007061554A2 (en) 2005-10-21 2007-05-31 Purdue Research Foundation Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
BRPI0617891A2 (pt) 2005-10-26 2011-08-09 Boehringer Ingelheim Int compostos de (hetero)arila com atividade antagonista de mch, sais fisiologicamente aceitáveis dos mesmos, composição, composição farmacêutica bem como uso e preparação dos ditos compostos
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc BI-aryl-meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20070149508A1 (en) 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
AU2006315514B2 (en) 2005-11-10 2012-03-01 Chemocentryx, Inc. Substituted quinolones and methods of use
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
EP1953147A1 (en) 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CA2631741C (en) 2005-12-02 2014-01-28 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ZA200804679B (en) 2005-12-08 2010-02-24 Millenium Pharmaceuticals Inc Bicyclic compounds with kinase inhibitory activity
WO2007066189A2 (en) 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
US8293746B2 (en) 2005-12-21 2012-10-23 Novartis Ag Pyrimidinyl aryl urea derivatives being FGF inhibitors
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007092879A2 (en) 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
WO2007109334A2 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. Sip receptor modulating compounds and use thereof
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2233472B1 (en) 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
CA2648324A1 (en) 2006-04-06 2007-10-18 Wisconsin Alumni Research Foundation 2-methylene-1.alpha.,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
US20090286813A1 (en) 2006-04-13 2009-11-19 Astrazeneca Ab Thioxanthine Derivatives and Their Use as Inhibitors of MPO
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
PT2027123E (pt) 2006-05-11 2011-05-30 Irm Llc Compostos e composi??es como inibidores da prote?na quinase
CA2650611A1 (en) * 2006-05-15 2007-11-29 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
JP2009541494A (ja) 2006-06-16 2009-11-26 アルベマール・コーポレーシヨン 爬虫類および／またはこれらの卵の中のサルモネラ菌を低減もしくは除去する方法
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
WO2008001070A1 (en) 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
WO2008005877A2 (en) 2006-06-30 2008-01-10 Board Of Regents, The University Of Texas System Inhibitors of c-kit and uses thereof
JP2009542604A (ja) 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008021851A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
US20100075947A1 (en) 2006-08-16 2010-03-25 Exelixis, Inc. Methods of Using PI3K and MEK Modulators
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
PT2061765E (pt) 2006-09-01 2015-02-06 Senhwa Biosciences Inc Moduladores de serina-treonina-proteína-quinase e de parp
US8268809B2 (en) 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008034859A1 (en) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008034860A1 (en) 2006-09-22 2008-03-27 Glaxo Group Limited Pyrrolo[2, 3-b]pyridin-4-yl-benzenesulfonamide compounds as ikk2 inhibitors
BRPI0717134A2 (pt) 2006-09-28 2013-10-15 Novartis Ag Derivados de pirazol [1,5-a] pirimidina e seu uso de terapêutico
US8202876B2 (en) 2006-10-02 2012-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
AR063420A1 (es) 2006-10-30 2009-01-28 Glaxo Group Ltd Derivados de 2-ciano-4-pirimidinil sustituidos,proceso de preparacion de los mismos,medicamentos que los contienen y su uso para el tratamiento de la malaria.
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
JP5244118B2 (ja) 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー 新規キナーゼ阻害剤
US7892454B2 (en) 2006-11-17 2011-02-22 Polyera Corporation Acene-based organic semiconductor materials and methods of preparing and using the same
EP2086974B1 (en) 2006-11-17 2013-07-24 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
KR20080045536A (ko) 2006-11-20 2008-05-23 에스케이케미칼주식회사 피리딘 화합물을 포함하는 간염 치료 및 예방 또는 간 보호효능을 갖는 약제 조성물
US20110262525A1 (en) 2006-12-13 2011-10-27 Schering Corporation Methods of treatment
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CN101679408B (zh) * 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
AU2007337895C1 (en) 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2008085942A2 (en) 2007-01-08 2008-07-17 Polyera Corporation Methods for preparing arene-bis(dicarboximide)-based semiconducting materials and related intermediates for preparing same
CN101007778A (zh) 2007-01-10 2007-08-01 复旦大学 一种链延长型芴基双马来酰亚胺及其制备方法
AU2008206406A1 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
TW200900061A (en) 2007-01-12 2009-01-01 Astellas Pharma Inc Condensed pyridine compound
FR2911604B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP5358962B2 (ja) 2007-02-06 2013-12-04 住友化学株式会社 組成物及び該組成物を用いてなる発光素子
JP2008198769A (ja) 2007-02-13 2008-08-28 Nippon Steel Chem Co Ltd 有機エレクトロルミネッセント素子
KR20090115953A (ko) 2007-03-06 2009-11-10 노파르티스 아게 염증성 또는 알레르기성 상태의 치료에 적합한 바이시클릭 유기 화합물
EP2134693A2 (en) 2007-03-07 2009-12-23 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
CA2702650C (en) 2007-03-12 2017-01-03 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
KR20080091948A (ko) 2007-04-10 2008-10-15 에스케이케미칼주식회사 락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
WO2008128141A2 (en) 2007-04-12 2008-10-23 Advanced Technology Materials, Inc. Zirconium, hafnuim, titanium, and silicon precursors for ald/cvd
MX2009011359A (es) 2007-04-20 2009-11-05 Schering Corp Derivados de pirimidinona y sus metodos de uso.
EP1985612A1 (en) 2007-04-26 2008-10-29 Bayer Schering Pharma Aktiengesellschaft Arymethylen substituted N-Acyl-gamma-aminoalcohols
WO2008141065A1 (en) 2007-05-10 2008-11-20 Smithkline Beecham Corporation Quinoxaline derivatives as p13 kinase inhibitors
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
CA2689282A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
US8163752B2 (en) 2007-06-07 2012-04-24 Merck, Sharp & Dohme Corp. Tricyclic anilide heterocyclic CGRP receptor antagonists
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
MX2009013728A (es) 2007-06-15 2010-01-25 Banyu Pharma Co Ltd Derivados de bicicloanilina.
CN102131828B (zh) 2007-06-18 2015-06-17 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
EP2018859A1 (en) 2007-07-26 2009-01-28 Bayer Schering Pharma Aktiengesellschaft Arylmethylene substituted N-acyl-beta-amino alcohols
ES2375425T3 (es) 2007-07-26 2012-02-29 Novartis Ag Compuestos org�?nicos.
EP2020404A1 (en) 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
US9493419B2 (en) 2007-08-21 2016-11-15 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2009029625A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. 4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
CA2698511C (en) 2007-09-04 2016-10-11 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009030871A1 (en) 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
WO2009046141A2 (en) 2007-10-01 2009-04-09 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2009044788A1 (ja) 2007-10-05 2009-04-09 Banyu Pharmaceutical Co., Ltd. ベンゾオキサジノン誘導体
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009049018A1 (en) 2007-10-10 2009-04-16 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009046606A1 (en) 2007-10-11 2009-04-16 Shanghai Institute Of Materia Medica, Cas Pyrimidinyl-propionic acid derivatives and their use as ppar agonists
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009047993A1 (ja) 2007-10-13 2009-04-16 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子、表示装置及び照明装置
US8129371B2 (en) 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
KR20100076022A (ko) 2007-10-17 2010-07-05 노파르티스 아게 Ａｌｋ 억제제로서 유용한 이미다조 [１,２-ａ] 피리딘 유도체
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
EP2215085B1 (en) 2007-10-25 2011-09-07 AstraZeneca AB Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
US8921336B2 (en) 2007-11-28 2014-12-30 Dana-Farber Cancer Institute, Inc. Small molecule myristate inhibitors of BCR-ABL and methods of use
EP2231620A1 (en) 2007-12-03 2010-09-29 Boehringer Ingelheim International GmbH Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
MX2010006457A (es) 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN101970441A (zh) 2007-12-21 2011-02-09 惠氏有限责任公司 作为肝脏x受体调节剂的咪唑并[1，2-b]哒嗪化合物
US8153827B2 (en) 2007-12-27 2012-04-10 Purdue Research Foundation Reagents for biomolecular labeling, detection and quantification employing Raman spectroscopy
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
KR20100121629A (ko) 2008-01-24 2010-11-18 유씨비 파마, 에스.에이. 시클로부톡시 기를 포함하는 화합물
US8629154B2 (en) 2008-01-24 2014-01-14 Andrey Alexandrovich Ivashchenko Substituted cycloalcano[e and d] pyrazolo [1,5-a]pyrimidines/antagonists of serotonin 5-HT6 receptors and methods for production and the use thereof
KR20100119776A (ko) 2008-01-24 2010-11-10 알라 캠, 엘엘씨 2-알킬아미노-3-아릴설포닐-사이클로알카노[ｅ 또는 ｄ]피라졸로[1,5-Ａ]피리미딘/세로토닌 5-ＨＴ6 수용체의 길항제, 이의 제조방법 및 이의 용도
ES2523169T3 (es) 2008-01-25 2014-11-21 High Point Pharmaceuticals, Llc Compuestos tricíclicos como moduladores de la síntesis de TNF y como inhibidores de PDE4
US8987280B2 (en) 2008-01-30 2015-03-24 Genentech, Inc. Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
US20110190263A1 (en) 2008-02-22 2011-08-04 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009103652A1 (en) 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CA2716128A1 (en) 2008-02-27 2009-09-03 Vitae Pharmaceuticals, Inc. Inhibitors of 11.beta.-hydroxysteroid dehydrogenase type 1
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
WO2009125808A1 (ja) 2008-04-11 2009-10-15 第一三共株式会社 アミノシクロヘキシル誘導体
WO2009125809A1 (ja) 2008-04-11 2009-10-15 第一三共株式会社 ピペリジン誘導体
EP2444403A1 (en) 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
NZ588830A (en) 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
JP5302389B2 (ja) 2008-04-29 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｊｎｋのピリミジニルピリドンインヒビター
EP2271943A1 (en) 2008-04-29 2011-01-12 Novartis AG Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
JP5351254B2 (ja) 2008-05-23 2013-11-27 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
WO2009144205A1 (en) 2008-05-30 2009-12-03 Basf Se Rylene-based semiconductor materials and methods of preparation and use thereof
JP2011522048A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
CN102089403A (zh) 2008-06-10 2011-06-08 巴斯夫欧洲公司 新型过渡金属配合物及其在有机发光二极管中的用途-ⅲ
US8507504B2 (en) 2008-06-12 2013-08-13 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
AU2009261683A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
JPWO2009157423A1 (ja) 2008-06-24 2011-12-15 財団法人乙卯研究所 縮合環を有するオキサゾリジノン誘導体
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
ES2552681T3 (es) 2008-07-15 2015-12-01 F. Hoffmann-La Roche Ag Nuevas fenil-imidazopiridinas y piridazinas
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
JP2011528368A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
AR072906A1 (es) 2008-08-06 2010-09-29 Novartis Ag Nucleosidos modificados utiles como antivirales
CN102177152A (zh) 2008-08-11 2011-09-07 哈佛大学校长及研究员协会 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2342191B1 (en) 2008-09-10 2013-03-20 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
WO2010038081A2 (en) 2008-10-03 2010-04-08 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20100267748A1 (en) 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US20100105655A1 (en) 2008-10-29 2010-04-29 Astrazeneca Ab Novel compounds 515
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010052448A2 (en) 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
WO2010059552A1 (en) 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
WO2010064621A1 (ja) 2008-12-03 2010-06-10 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
BRPI0922224A2 (pt) 2008-12-08 2016-08-02 Vm Pharma Llc composições de inibidores de proteína tirosina quiinase receptora.
MA32948B1 (fr) 2008-12-09 2012-01-02 Genentech Inc Anticorps anti-pd-l1 et leur utilisation pour ameliorer la fonction des lymphocytes t
US8110265B2 (en) 2008-12-09 2012-02-07 The Coca-Cola Company Pet container and compositions having enhanced mechanical properties and gas barrier properties
AU2009325398A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
US8575179B2 (en) 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
AU2009335843A1 (en) 2008-12-19 2011-07-21 Abbvie Inc. Heterocyclic compounds and methods of use
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
AU2009335016A1 (en) 2008-12-30 2011-08-18 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
CA2748491C (en) 2008-12-30 2019-08-06 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010083145A1 (en) 2009-01-16 2010-07-22 Merck Sharp & Dohme Corp. IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
DE102009007038A1 (de) 2009-02-02 2010-08-05 Merck Patent Gmbh Metallkomplexe
JP2010180147A (ja) 2009-02-04 2010-08-19 Mitsubishi Gas Chemical Co Inc シアン酸エステル化合物、およびその硬化物
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
WO2010103306A1 (en) 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
JP5615261B2 (ja) 2009-03-11 2014-10-29 学校法人関西学院 多環芳香族化合物
EP2408744A1 (en) 2009-03-18 2012-01-25 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US8491869B2 (en) 2009-03-23 2013-07-23 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
US8481525B2 (en) 2009-04-06 2013-07-09 University Of Health Network Kinase inhibitors and method of treating cancer with same
KR101675607B1 (ko) 2009-04-07 2016-11-11 에머리티 파마 아베 치료제로서 이소옥사졸-3(2ｈ)-온 유사체
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JP5531446B2 (ja) 2009-04-20 2014-06-25 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置および照明装置
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
ES2347630B1 (es) 2009-04-29 2011-09-08 Universitat Ramon Llull Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
US20100280067A1 (en) 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
JP5616434B2 (ja) 2009-05-01 2014-10-29 ハートサイン テクノロジーズ リミテッド 体外式除細動器
JO2860B1 (en) 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds
JP5600891B2 (ja) 2009-05-15 2014-10-08 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置および照明装置
JP5604808B2 (ja) 2009-05-20 2014-10-15 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5629980B2 (ja) 2009-05-22 2014-11-26 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5568889B2 (ja) 2009-05-22 2014-08-13 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置、照明装置及び有機エレクトロルミネッセンス素子材料
US8637465B2 (en) 2009-05-27 2014-01-28 Kobenhavns Universitet Fibroblast growth factor receptor-derived peptides binding to NCAM
JP5499519B2 (ja) 2009-05-27 2014-05-21 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP5600894B2 (ja) 2009-06-24 2014-10-08 コニカミノルタ株式会社 白色有機エレクトロルミネッセンス素子、表示装置及び照明装置
HUE033442T2 (en) 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
JP5732673B2 (ja) 2009-06-30 2015-06-10 日本ゼオン株式会社 新規なジアリールアミン化合物、並びに、老化防止剤、ポリマー組成物、ゴム架橋物、及び、その成形品、並びに、ジアリールアミン化合物の製造方法
WO2011007819A1 (ja) 2009-07-17 2011-01-20 塩野義製薬株式会社 ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
WO2011011597A1 (en) 2009-07-24 2011-01-27 Duke University Prochelators useful for inhibiting metal-associated toxicity
FR2948568B1 (fr) 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
SG178106A1 (en) 2009-08-05 2012-03-29 Versitech Ltd Antiviral compounds and methods of making and using thereof
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
BR112012008094A2 (pt) 2009-08-07 2020-08-18 Chugai Seiyaku Kabushiki Kaisha derivado de aminopirazol, seu uso, composição farmacêutica que o compreende, agentes para inibir a atividade de fgfr e para prevenir ou tratar câncer
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
JP5577650B2 (ja) 2009-08-24 2014-08-27 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101184115B1 (ko) 2009-08-31 2012-09-18 일동제약주식회사 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
AU2010289397B2 (en) 2009-09-03 2016-05-26 Bioenergenix Heterocyclic compounds for the inhibition of PASK
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
US9481675B2 (en) 2009-09-11 2016-11-01 Merck Sharp & Dohme Corp. Gyrase inhibitors
EP2483275B1 (en) 2009-10-01 2014-10-15 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
KR20110043270A (ko) 2009-10-21 2011-04-27 (주)씨에스엘쏠라 유기발광화합물 및 이를 구비한 유기발광소자
SG10201406813RA (en) 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
CN102596916B (zh) 2009-10-30 2015-06-17 诺瓦提斯公司 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
PE20121327A1 (es) 2009-11-06 2012-10-18 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
US8629132B2 (en) 2009-11-13 2014-01-14 Genosco Kinase inhibitors
MY156210A (en) 2009-11-18 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011062885A1 (en) 2009-11-23 2011-05-26 Schering Corporation Fused bicyclic pyrimidine derivatives and methods of use thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP2332939A1 (en) * 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
AU2010326030A1 (en) 2009-12-01 2012-06-07 Abbvie Inc. Novel tricyclic compounds
JP2011116840A (ja) 2009-12-02 2011-06-16 Fujifilm Corp 顔料微粒子分散体、これを用いた光硬化性組成物及びカラーフィルタ
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
MX2012007154A (es) 2009-12-17 2012-08-01 Merck Sharp & Dohme Aminopirimidinas como inhibidores de syk.
JP2013514986A (ja) 2009-12-18 2013-05-02 ノバルティス アーゲー 血液癌の処置方法
SG10201502073PA (en) 2009-12-22 2015-05-28 Vertex Pharma Isoindolinone inhibitors of phosphatidylinositol 3-kinase
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
FR2954315B1 (fr) 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
US20130096115A1 (en) 2009-12-28 2013-04-18 Afraxis, Inc. Methods for treating autism
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
JP2013515785A (ja) 2009-12-29 2013-05-09 ポリエラ コーポレイション 有機半導体としてのチオン酸化芳香族ビスイミドおよびそれを組み込む装置
WO2011082267A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrazine compounds
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
JP2013516420A (ja) 2009-12-30 2013-05-13 アークル インコーポレイテッド 置換されたピロロ−アミノピリミジン化合物
CN102115026A (zh) 2009-12-31 2011-07-06 清华大学 一维纳米结构、其制备方法及一维纳米结构作标记的方法
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
AR079975A1 (es) 2010-01-06 2012-03-07 British Columbia Cancer Agency Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2789344A1 (en) 2010-02-15 2011-08-18 Jeremy Earle Wulff Synthesis of bicyclic compounds and method for their use as therapeutic agents
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
AU2011218167B2 (en) 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
CN103740434B (zh) 2010-02-18 2016-02-03 Ntn株式会社 增稠剂、润滑脂及它们的制造方法以及润滑脂封入轴承
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011103557A1 (en) 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
KR101719173B1 (ko) 2010-02-26 2017-03-23 신닛테츠 수미킨 가가쿠 가부시키가이샤 유기 전계 발광 소자
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
US20110237599A1 (en) 2010-03-10 2011-09-29 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
AU2011227643A1 (en) 2010-03-16 2012-09-20 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
KR20180032686A (ko) 2010-03-24 2018-03-30 아미텍 테러퓨틱 솔루션즈 인크 인산화효소 억제에 유용한 헤테로환 화합물
US8791257B2 (en) 2010-03-31 2014-07-29 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
CN102153551B (zh) 2010-04-02 2012-04-25 济南海乐医药技术开发有限公司 基于吲唑或氮杂吲唑的双芳基脲或硫脲类结构抗肿瘤药物
JP5724204B2 (ja) 2010-04-07 2015-05-27 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置、及び照明装置
JP6067550B2 (ja) 2010-04-13 2017-01-25 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
PT2558095T (pt) 2010-04-16 2019-01-29 Novartis Ag Composto orgânico para utilização no tratamento do cancro hepático
WO2011133750A1 (en) 2010-04-22 2011-10-27 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133722A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
US8759398B2 (en) 2010-05-03 2014-06-24 Biolink Life Sciences, Inc. Phosphorus binder composition for treatment of hyperphosphatemia
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
BR112012028764A2 (pt) 2010-05-11 2017-03-14 Aveo Pharmaceuticals Inc anticor-pos antifgfr2
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
EP2569310A1 (en) 2010-05-11 2013-03-20 Pfizer Inc Morpholine compounds as mineralocorticoid receptor antagonists
CN103037870B (zh) 2010-05-12 2016-05-25 斯派克托姆制药公司 碱式碳酸镧、碳酸氧镧及其制造方法和用途
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
WO2011147198A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
WO2011151360A1 (en) 2010-06-04 2011-12-08 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2011155983A1 (en) 2010-06-07 2011-12-15 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US8683564B2 (en) 2010-06-27 2014-03-25 King Saud University One-time password authentication with infinite nested hash claims
ES2706066T3 (es) 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
JP2013530199A (ja) 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
AU2011276955B2 (en) 2010-07-09 2014-11-06 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012008999A2 (en) 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
EP2594566A4 (en) 2010-07-16 2014-10-01 Kyowa Hakko Kirin Co Ltd AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
WO2012008564A1 (ja) 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
EP2413140A1 (en) 2010-07-29 2012-02-01 Sanofi Method for identifying a compound having an antiarrhythmic effect as well as uses relating thereto
CN103140564B (zh) 2010-07-30 2015-11-25 罗门哈斯电子材料韩国有限公司 使用电致发光化合物作为发光材料的电致发光器件
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012027239A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
KR101837223B1 (ko) 2010-09-01 2018-03-09 질레드 코네티컷 인코포레이티드 피리디논/피라지논, 그의 제조 방법 및 사용 방법
KR20180031823A (ko) 2010-09-01 2018-03-28 질레드 코네티컷 인코포레이티드 피리다지논, 그의 제조 방법 및 사용 방법
AR082799A1 (es) 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
EP2614058B1 (en) 2010-09-08 2015-07-08 GlaxoSmithKline Intellectual Property Development Limited POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CN103238117A (zh) 2010-09-14 2013-08-07 保土谷化学工业株式会社 电荷控制剂和使用其的调色剂
CN102399220A (zh) 2010-09-15 2012-04-04 黄振华 三并环类PI3K和mTOR双重抑制剂
CN102399233B (zh) 2010-09-15 2014-08-13 山东轩竹医药科技有限公司 PI3K和mTOR双重抑制剂类化合物
WO2012036233A1 (ja) 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JO3062B1 (ar) 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
EP2629777B1 (en) 2010-10-22 2018-12-19 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
RU2621674C2 (ru) 2010-10-25 2017-06-07 Г1 Терапьютикс Инк., Ингибиторы cdk
JP2012092049A (ja) 2010-10-27 2012-05-17 Sumitomo Chemical Co Ltd 有害動物防除組成物及び有害動物の防除方法
EP2886120B1 (en) 2010-10-29 2019-06-19 Emory University Quinazoline derivatives, compositions and uses related thereto
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
CA2816769A1 (en) 2010-11-10 2012-05-18 Gruenenthal Gmbh Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands
WO2012063207A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
JP2012116825A (ja) 2010-11-11 2012-06-21 Ehime Univ アセンジイミド化合物の製造方法
KR101171232B1 (ko) 2010-11-15 2012-08-06 단국대학교 산학협력단 스파이로 화합물 및 이를 포함하는 유기전계 발광소자
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
EP2640715A1 (en) 2010-11-17 2013-09-25 Amgen Inc. Quinoline derivatives as pik3 inhibitors
KR101817221B1 (ko) 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2796456A1 (en) 2010-12-09 2014-10-29 Amgen Inc. Bicyclic compounds as Pim inhibitors
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
PL2655357T3 (pl) 2010-12-20 2016-12-30 Pochodne triazolowe indazolilowe jako inhibitory irak
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
BR112013015855A2 (pt) 2010-12-22 2018-06-05 Leo Laboratories Ltd composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
EP2655312A1 (en) 2010-12-22 2013-10-30 Leo Laboratories Limited 3-acyl-ingenols ii
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
MX2013007261A (es) 2010-12-23 2013-11-04 Amgen Inc Compuestos heterociclicos y sus usos.
JP5691508B2 (ja) 2010-12-27 2015-04-01 Jnc株式会社 ジイミド化合物ならびにインクジェット用インクおよびその用途
KR101466150B1 (ko) 2010-12-31 2014-11-27 제일모직 주식회사 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
CN103328488B (zh) 2011-01-06 2015-12-09 吉坤日矿日石能源株式会社 酰亚胺化合物及其制造方法、润滑脂用增稠剂和润滑脂组合物
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
FR2970967B1 (fr) 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
CA2829988A1 (en) 2011-03-17 2012-09-20 Novartis Ag Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
AU2012230896B9 (en) 2011-03-23 2015-06-18 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
ITPD20110091A1 (it) 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
US8802711B2 (en) 2011-03-25 2014-08-12 Abbvie Inc. TRPV1 antagonists
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
FR2974088A1 (fr) 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
CN103596980B (zh) 2011-05-16 2017-08-08 霍夫曼-拉罗奇有限公司 Fgfr1激动剂及使用方法
CA2836203A1 (en) 2011-05-17 2012-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
MX2013013437A (es) 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
CA2837630A1 (en) 2011-06-01 2012-12-06 Knut Eis Substituted aminoimidazopyridazines
UY34114A (es) 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
EP2719741B1 (en) 2011-06-13 2016-04-13 LG Chem, Ltd. Novel compounds and organic electronic device using same
WO2012175591A1 (en) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
EP2742049A1 (en) 2011-08-12 2014-06-18 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and jak inhibitors
CA2838784A1 (en) 2011-08-12 2013-02-21 F. Hoffmann-La Roche Ag Pyrazolo[3,4-c]pyridine compounds and methods of use
JP2013049251A (ja) 2011-08-31 2013-03-14 Fujifilm Corp レーザー彫刻用レリーフ印刷版原版、並びに、レリーフ印刷版及びその製版方法
WO2013033981A1 (zh) 2011-09-06 2013-03-14 江苏先声药物研究有限公司 一类2,7-萘啶衍生物及其制备方法和应用
EP2755482B1 (en) 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
US9320737B2 (en) 2011-09-23 2016-04-26 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US9376435B2 (en) 2011-09-23 2016-06-28 Jawaharlal Nehru Centre For Advanced Scientific Research Chromophores for the detection of volatile organic compounds
SG11201401082XA (en) 2011-09-30 2014-04-28 Kineta Inc Anti-viral compounds
UA111382C2 (uk) 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
EP2766352B1 (en) 2011-10-12 2018-06-06 University Health Network (UHN) Indazole compounds as kinase inhibitors and method of treating cancer with same
KR101897044B1 (ko) 2011-10-20 2018-10-23 에스에프씨 주식회사 유기금속 화합물 및 이를 포함하는 유기전계발광소자
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
US20140288073A1 (en) 2011-10-28 2014-09-25 Novartis Ag Method of Treating Gastrointestinal Stromal Tumors
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
FR2985257B1 (fr) 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985258A1 (fr) 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
US10026905B2 (en) 2012-01-18 2018-07-17 Duk San Neolux Co., Ltd. Compound, organic electric element using the same, and an electronic device thereof
WO2013109027A1 (ko) 2012-01-18 2013-07-25 덕산하이메탈(주) 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
JP5355825B1 (ja) 2012-01-19 2013-11-27 大鵬薬品工業株式会社 ３，５−二置換ベンゼンアルキニル化合物及びその塩
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
JP2013179181A (ja) 2012-02-28 2013-09-09 Sumitomo Chemical Co Ltd 有機光電変換素子
JP6431770B2 (ja) 2012-03-14 2018-11-28 ルピン・リミテッド Ｍｅｋインヒビターとしてのヘテロシクリル化合物
AU2013241664B2 (en) 2012-03-30 2016-05-19 Novartis Ag FGFR inhibitor for use in the treatment of hypophosphatemic disorders
JP5120580B1 (ja) 2012-05-14 2013-01-16 Ｊｓｒ株式会社 液晶配向剤
EP2852354B1 (en) 2012-05-20 2020-05-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Prosthetic mitral valve
EA036592B1 (ru) 2012-06-13 2020-11-26 Инсайт Холдингс Корпорейшн Замещенные трициклические соединения как ингибиторы fgfr
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
AU2013289175A1 (en) 2012-07-11 2015-01-22 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
KR101985259B1 (ko) 2012-08-10 2019-06-03 제이에스알 가부시끼가이샤 액정 배향제 및 화합물
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
WO2014062454A1 (en) 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
KR102000211B1 (ko) 2012-10-29 2019-09-30 삼성디스플레이 주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
US20140148548A1 (en) 2012-11-28 2014-05-29 Central Glass Company, Limited Fluorine-Containing Polymerizable Monomer And Polymer Compound Using Same
CN104968664A (zh) 2012-12-12 2015-10-07 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的并环化合物
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
WO2014105849A1 (en) 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
KR102030587B1 (ko) 2013-01-09 2019-10-10 에스에프씨주식회사 두 개의 나프틸기를 포함하는 비대칭 안트라센 유도체 및 이를 포함하는 유기 발광 소자
EP2945623B1 (en) 2013-01-15 2018-09-05 Suzhou Kintor Pharmaceuticals, Inc. Hedgehog pathway signaling inhibitors and therapeutic applications thereof
CN103694236B (zh) 2013-01-15 2017-05-31 苏州开拓药业股份有限公司 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物
KR101456626B1 (ko) 2013-02-01 2014-11-03 대영이앤비 주식회사 냉장고 부압 방지 장치
JP6311093B2 (ja) 2013-03-07 2018-04-18 国立大学法人九州大学 超分子複合体、発光体、および有機化合物検出用のセンサー素子
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9771327B2 (en) 2013-03-13 2017-09-26 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis
BR112015021701A2 (pt) 2013-03-14 2017-07-18 Abbvie Deutschland novos compostos inibidores da fosfoestearase tipo 10a
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CN111793068A (zh) 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑
KR101573611B1 (ko) 2013-04-17 2015-12-01 주식회사 엘지화학 플러렌 유도체, 이를 이용한 유기 태양 전지 및 이의 제조 방법
EP2986630B1 (en) 2013-04-19 2018-08-15 Covagen AG Novel bispecific binding molecules with antitumoral activity
CN109912594A (zh) 2013-04-19 2019-06-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP2994470B1 (en) 2013-05-09 2018-04-18 Principia Biopharma Inc. Pyrido[2,3-d]pyrimidine derivatives as fibroblast growth factor inhibitors
KR20160021134A (ko) 2013-06-14 2016-02-24 사노피 방광암 치료용 피라졸로피리딘 유도체
US9670203B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
WO2014206344A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
ES2807599T3 (es) 2013-07-02 2021-02-23 Syngenta Participations Ag Heterociclos bi- o tricíclicos activos como plaguicidas con sustituyentes que contienen azufre
JP6018547B2 (ja) 2013-07-09 2016-11-02 大成ロテック株式会社 舗装機械
WO2015006492A1 (en) 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AU2014287016B2 (en) 2013-07-11 2018-11-01 Acea Biosciences Inc. Pyrimidine derivatives as kinase inhibitors
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
MY184733A (en) 2013-10-18 2021-04-20 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
MX367723B (es) 2013-10-25 2019-09-03 Novartis Ag Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4.
MX2016005297A (es) 2013-10-25 2016-08-12 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos.
FR3012330B1 (fr) 2013-10-29 2015-10-23 Oreal Composition biphase comprenant un ester d'acide gras et de sucre ou un alkylpolyglucoside liquide, de hlb < 8, et un alcane ramifie en c8-c18
WO2015066452A2 (en) 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
EP3184521B1 (en) 2014-08-19 2021-10-06 Shanghai Haihe Pharmaceutical Co., Ltd. Indazole compounds as fgfr kinase inhibitors, preparation and use thereof
CN104262330B (zh) 2014-08-27 2016-09-14 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CU20170029A7 (es) 2014-09-19 2017-08-08 Bayer Pharma AG Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3259246B1 (en) 2015-02-20 2023-03-22 Oregon Health & Science University Derivatives of sobetirome
MA51229A (fr) 2015-02-20 2021-03-24 Incyte Corp Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10363220B2 (en) 2015-06-03 2019-07-30 Triastek, Inc. Compartmented pharmaceutical dosage forms
SG10201912066SA (en) 2015-07-15 2020-02-27 Protagonist Therapeutics Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
RS58929B1 (sr) 2015-07-15 2019-08-30 Hoffmann La Roche Derivati etinila kao modulatori metabotropnih glutamatnih receptora
CN108026315B (zh) 2015-07-15 2021-02-09 卡博特公司 制造用硅石增强的弹性体复合物的方法以及包含其的制品
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
MX2018001227A (es) 2015-07-30 2018-03-26 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas.
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
EP3337787B1 (en) 2015-08-20 2021-03-03 JS InnoPharm (Shanghai) Ltd. 1h-pyrazolo[3,4-b]pyridine, 1h-thieno[2,3-c]pyrazole and 1h-indazole carboxamide derivatives and related compounds as extracellular signal-regulated kinases (erk) inhibitors for treating cancer
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
CA3002560A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
EA201891203A1 (ru) 2015-11-19 2018-12-28 Инсайт Корпорейшн Гетероциклические соединения в качестве иммуномодуляторов
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112018012756A2 (pt) 2015-12-22 2018-12-04 Incyte Corp compostos heterocíclicos como imunomoduladores
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
RS63673B1 (sr) 2016-06-20 2022-11-30 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3523306A4 (en) 2016-10-05 2020-05-06 Recurium IP Holdings, LLC SPIROCYCLIC COMPOUNDS
KR101755556B1 (ko) 2016-11-18 2017-07-07 주식회사 케마스 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101834366B1 (ko) 2016-11-21 2018-03-05 주식회사 케마스 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101844049B1 (ko) 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MY197635A (en) 2016-12-22 2023-06-29 Incyte Corp Benzooxazole derivatives as immunomodulators
TWI798192B (zh) 2016-12-22 2023-04-11 美商英塞特公司 免疫調節劑化合物及使用方法
ES2918974T3 (es) 2016-12-22 2022-07-21 Incyte Corp Compuestos heteroaromaticos biciclicos como inmunomoduladores
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018234354A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
WO2019037640A1 (en) 2017-08-22 2019-02-28 Js Innopharm (Shanghai) Ltd HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USING THE SAME
WO2019079369A1 (en) 2017-10-19 2019-04-25 Effector Therapeutics, Inc. BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2
ES2908283T3 (es) 2017-12-02 2022-04-28 Galapagos Nv Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CN112996506A (zh) 2018-08-14 2021-06-18 奥斯特克有限公司 吡咯并二吡啶化合物
CN112654396A (zh) 2018-09-07 2021-04-13 默克专利股份公司 5-吗啉-4-基-吡唑并[4,3-b]吡啶衍生物
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
JP7148802B2 (ja) 2019-01-25 2022-10-06 富士通株式会社 解析プログラム、解析方法および解析装置
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Also Published As

Publication number Publication date
US10040790B2 (en) 2018-08-07
BR112015026307A2 (pt) 2017-10-10
SG10201708520YA (en) 2017-12-28
KR20150143707A (ko) 2015-12-23
US9533984B2 (en) 2017-01-03
EP2986610B1 (en) 2017-12-27
NO3087075T3 (ru) 2018-07-14
LT2986610T (lt) 2018-04-10
PL2986610T4 (pl) 2019-06-28
JP2016518372A (ja) 2016-06-23
US11530214B2 (en) 2022-12-20
EP3318564A2 (en) 2018-05-09
US20140315902A1 (en) 2014-10-23
SG11201508328PA (en) 2015-11-27
WO2014172644A3 (en) 2014-12-18
ECSP15048555A (es) 2017-07-31
CN105263931B (zh) 2019-01-25
US20190062327A1 (en) 2019-02-28
CA2909207A1 (en) 2014-10-23
EP2986610A2 (en) 2016-02-24
AU2020250201A1 (en) 2020-11-05
JP6449244B2 (ja) 2019-01-09
CN109912594A (zh) 2019-06-21
JP6698799B2 (ja) 2020-05-27
US10450313B2 (en) 2019-10-22
PT2986610T (pt) 2018-03-09
ES2657451T9 (es) 2018-12-11
IL262038A (en) 2018-11-29
PH12015502383A1 (en) 2016-02-22
US20200095244A1 (en) 2020-03-26
AU2014253798B2 (en) 2018-08-09
EP3318564B1 (en) 2021-07-28
KR102469849B1 (ko) 2022-11-23
HUE036571T2 (hu) 2018-07-30
AU2018208772B2 (en) 2020-07-09
CA2909207C (en) 2021-11-02
ME03015B (me) 2018-10-20
US20210395246A1 (en) 2021-12-23
CA3130452A1 (en) 2014-10-23
AU2018208772A1 (en) 2018-08-16
AR096097A1 (es) 2015-12-09
JP6903790B2 (ja) 2021-07-14
JP2019069953A (ja) 2019-05-09
AU2020250201B2 (en) 2022-07-07
DK2986610T5 (en) 2018-12-10
DK2986610T3 (en) 2018-02-12
TWI715901B (zh) 2021-01-11
US10947230B2 (en) 2021-03-16
TWI649318B (zh) 2019-02-01
TW201512195A (zh) 2015-04-01
RS56924B9 (sr) 2019-09-30
AU2014253798A1 (en) 2015-10-29
CL2015003089A1 (es) 2016-04-22
ES2893725T3 (es) 2022-02-09
IL241982B (en) 2021-02-28
EP2986610B9 (en) 2018-10-17
PE20152033A1 (es) 2016-01-21
US20170166564A1 (en) 2017-06-15
NZ752422A (en) 2020-09-25
EA202090516A3 (ru) 2020-10-30
WO2014172644A2 (en) 2014-10-23
CR20150578A (es) 2016-02-29
CN109776525A (zh) 2019-05-21
PH12019502810A1 (en) 2021-01-11
MX367878B (es) 2019-09-10
CN109776525B (zh) 2022-01-21
HRP20180365T1 (hr) 2018-04-20
JP2020128396A (ja) 2020-08-27
CA3130452C (en) 2023-10-31
CY1120556T1 (el) 2019-07-10
HK1255159A1 (zh) 2019-08-09
MX2015014683A (es) 2016-07-05
NZ713074A (en) 2020-09-25
HRP20180365T2 (hr) 2019-06-28
EP3318564A3 (en) 2018-08-15
ES2657451T3 (es) 2018-03-05
IL262038B (en) 2022-06-01
HK1221462A1 (zh) 2017-06-02
BR112015026307B1 (pt) 2022-03-22
KR20210079398A (ko) 2021-06-29
AU2014253798C1 (en) 2019-02-07
KR102269032B1 (ko) 2021-06-24
UA120087C2 (uk) 2019-10-10
CN105263931A (zh) 2016-01-20
PL2986610T3 (pl) 2018-05-30
EA035095B1 (ru) 2020-04-27
MY181497A (en) 2020-12-23
TW201920173A (zh) 2019-06-01
MX2019010709A (es) 2019-10-21
RS56924B1 (sr) 2018-05-31
EA201592005A1 (ru) 2016-02-29
SI2986610T1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
EA202090516A2 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
PH12017501481B1 (en) Bicyclic heterocycles as fgfr inhibitors
CL2016002394A1 (es) Derivados de quinolina como inhibidores de smo
MX2016005297A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos.
CL2015002932A1 (es) Inhibidores de proteína quinasa
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201590850A1 (ru) Трициклические конденсированные производные тиофена как ингибиторы jak
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
EA201792380A1 (ru) Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен
EA202190877A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA202091923A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
EA201691620A1 (ru) Циклопропиламины в качестве ингибиторов lsd1